{"entity":{"id":"nbe-therapeutics","kind":"company","name":"NBE-Therapeutics","aka":[],"tldr":"NBE-Therapeutics, founded in Basel in 2012 and owned by Boehringer Ingelheim since 2020, builds antibody-drug conjugates that pair its own conjugation chemistry with a PNU-derived anthracycline payload, designed to kill tumour cells directly and to trigger a lasting immune response against the tumour. Its candidates are still moving towards the clinic.","summary":"NBE-Therapeutics AG, founded in Basel in 2012, developed a next-generation antibody-drug conjugate platform for solid tumours combining its own conjugation technology, a PNU-derived anthracycline payload and antibody discovery capabilities. Its immune-stimulating ADC (iADC) concept aims for a long-lasting immuno-oncology effect in addition to direct cytotoxicity, with a pipeline of ADC candidates at various stages of development moving towards the clinic. The company became a wholly owned subsidiary of Boehringer Ingelheim in 2020 and in April 2025 opened a new ADC research and development centre in Basel that serves as a hub for Boehringer's ADC work.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nbe-therapeutics.com/"},{"label":"Boehringer Ingelheim opens NBE R&D centre (states 2020 acquisition)","url":"https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc","immune-stimulating-adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Boehringer Ingelheim's own acquisition release (reported elsewhere as up to EUR 1.18 billion, December 2020) is rendered client-side and returned no text to my fetches, so the deal value is omitted. Lead programme target (reported elsewhere as ROR1 for NBE-002) not stated on fetched pages."],"hq":"Basel","country":"CH","companyType":"biotech","website":"https://nbe-therapeutics.com/","founded":2012,"stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2020,"source":"https://nbe-therapeutics.com/news-events/news/boehringer-ingelheim-strengthens-antibody-drug-conjugate-portfolio-with-new-nbe-therapeutics-r-d-center-in-basel","note":"Company states it became part of Boehringer Ingelheim in 2020; deal value not stated on the fetched page"}],"acquiredBy":"boehringer-ingelheim"},"route":"/companies/nbe-therapeutics/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"immune-stimulating-adc","kind":"technology","name":"Immune-stimulating antibody conjugate (ISAC)","route":"/technologies/immune-stimulating-adc/"}],"company":[{"id":"boehringer-ingelheim","kind":"company","name":"Boehringer Ingelheim","route":"/companies/boehringer-ingelheim/"}]}}